Complementary and alternative therapies for Crohn’s disease, like acupuncture and meditation, are useful approaches to managing symptoms in combination with a treatment plan.

The FDA approval of Selarsdi 130 mg/26 ml in a single-dose vial for intravenous infusion expands the label to include ...

Breastfeeding, child nutrition and exposure to secondhand tobacco smoke at an early age may play a role in the onset of ...

After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...

Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...

There is a strong connection between inflammatory bowel disease (IBD) and spondyloarthritis—a condition that causes pain and ...

Eli Lilly and Johnson & Johnson both touted data Monday for their IL-23 inhibitors in Crohn’s disease, with Lilly also ...

Crohn’s disease is a type of inflammatory bowel disease (IBD) that involves periods of remission and flares. Symptoms can ...

Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...

A phase 3 study found that a subcutaneous version of Johnson & Johnson's Tremfya (guselkumab) was effective in treating Crohn ...

Johnson & Johnson's Tremfya shows promising results in Phase 3 GRAVITI study for Crohn's disease, achieving significant clinical remission and endoscopic response at 48 weeks.

Johnson & Johnson announced results from the Phase 3 GRAVITI study of Tremfya – guselkumab -, the first and only IL-23 inhibitor, ...